Dermatology

These data highlight the comparability of Humira, the adalimumab originator, to the drug’s biosimilars in terms of efficacy in treating psoriasis.

In this analysis, French investigators highlight patient and clinician perspectives on 1-year use of tildrakizumab for moderate-to-severe psoriasis.

These data highlight the long-term maintenance of bimekizumab responses among individuals with psoriasis, looking at bio-naïve and bio-switched patients.

This interview with Ian Myles, MD, MPH, highlights his team’s recent findings on identifying dermatitis related to topical steroid withdrawal (TSW) versus atopic dermatitis.

These data highlight differences and similarities among dermatologists globally in their decisions related to the treatment of mild-to-moderate atopic dermatitis.

Baricitinib treatment was safe among patients with alopecia areata over 48 weeks in a real-world treatment setting.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode highlights 5 key dermatology updates from the 2025 American Academy of Dermatology Annual Meeting in Orlando.

Investigators highlight systemic treatments for psoriatic disease that maintain lower rates of serious infections among older adults suffering from psoriatic disease.

These recent data demonstrate small doses of doxycycline, an anti-inflammatory medication, may help manage lymphocytic scarring alopecia.

This March 2025 SOCS News Update highlights misconceptions related to skin health, the value of diversity in clinical research, and SOCS Symposium highlights.

Jolanta Bernatoniene, PhD, discussed positive results from the APeX-P study of oral berotralstat in children with hereditary angioedema.

These data highlight the potential benefit of continuous treatment with subcutaneous spesolimab for generalized pustular psoriasis (GPP).

This interview with Christopher Sayed, MD, features a discussion about his team’s recent findings on bimekizumab for hidradenitis suppurativa.

Latanya Benjamin, MD, and Lindsay Ackerman, MD, joins The Medical Sisterhood in a live recording at AAD 2025 to discuss advocacy, mentorship, and empowerment.

These pivotal phase 3 data on povorcitinib were the results of the STOP-HS clinical trial, with results suggesting both efficacy and safety for hidradenitis suppurativa.

This quiz, the fourth in this series, assesses your knowledge in post-AK treatment surveillance strategies, risk stratification, and more.

A recap of the 7 phase 3 trials presented during the 2025 AAD annual meeting's late-breaking sessions.

This interview highlights recent findings on roflumilast cream 0.05% for patients aged 2 to 5 years with mild to moderate atopic dermatitis.

New data presented at AAD 2025 point to impacts on multiple disease nodes as needed to achieve high levels of efficacy.

This interview with Yamauchi highlights phase 3b findings on tildrakizumab among patients with moderate-to-severe nail psoriasis.

These data, presented at AAD 2025, highlight the efficacy of upadacitinib in clearing skin among patients with atopic dermatitis compared to those given dupilumab.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key dermatology updates from the 2025 American Academy of Allergy, Asthma, and Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress.

Carolyn Goh, MD, spoke in this AAD 2025 interview about her talk on guidance in addressing patients with hair disorders.

A group of 9 experts reflect on what they are looking forward to most in 2025 following the AAD annual meeting.

Andrew Alexis, MD, MPH, highlights his ‘What’s New’ talk at AAD 2025 on new practices for treating pigmentary disorders such as vitiligo.